08:05 AM EDT, 05/08/2025 (MT Newswires) -- Insmed ( INSM ) reported a Q1 net loss Thursday of $1.42 per diluted share, widening from a loss of $1.06 a year earlier.

Analysts polled by FactSet expected a loss of $1.34.

ARIKAYCE product revenue for the quarter ended March 31 was $92.8 million, up from $75.5 million a year earlier. ARIKAYCE is an inhaled antibiotic.

Analysts surveyed by FactSet expected $91.5 million.

For 2025, the biotech company continues to expect global ARIKAYCE product revenue of $405 million to $425 million. Analysts polled by FactSet expect $468.4 million.

Shares of the company were down aroun 0.04% in recent Thursday premarket activity.